Inhibition of cedar pollen allergy by continuous intake of lactic acid bacteria

Inhibition of cedar pollen allergy by continuous intake of lactic acid bacteria - Inhibition of allergy by intake of lactic acid bacteria

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000034239

Enrollment

Registered

2018-09-23

Start date

2018-09-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Lactic acid bacteria, one tablet/day, 8 consecutive weeks Placebo, one tablet/day, 8 consecutive weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Subjects who obtained written consent regarding participation in research 2) Healthy adults aged 20 years or over, 65 years old or younger at the time of consent acquisition 3) Subjects who do not appear symptoms of allergic rhinitis in a period of not scattering cedar pollen, and do not need the medications 4) Subjects who the cedar pollen-specific IgE value is 2 or more 5) Subjects judged as appropriate for the study by the investigator in the medical examination

Exclusion criteria

Exclusion criteria: 1) Pregnant women or women with potential for pregnancy, and women who want pregnancy during this study 2) Lactating women 3) Subjects with severe disease of respiratory disease, heart disease, liver disease, kidney disease, diabetes, autoimmune disease or those with a past history 4) Subjects who have acute rhinitis, sinusitis, hypertrophic rhinitis 5) Subjects who have bronchial asthma combined 6) Those who are undergoing treatment (sublingual immunotherapy, etc.) that affects the results of the study 7) Subjects receiving treatment for antihistamines, anti-leukotriene drugs, steroids for nasal spray, oral steroids, immunotherapy 8) Subjects with milk allergy 9) Subjects who regularly intake foods rich in lactic acid bacteria (kimchi, pickles, beverages containing lactic acid bacteria, yoghurt, food for specified health uses, foods with function claims, supplements) and pharmaceuticals (Biofermin, etc) 10) Subjects who regularly intake anti-allergic foods 11) Subjects who make a blood donation of 400 ml within 12 weeks before the preliminary medical examination or that of 200 ml within 4weeks before the preliminary medical examination 12) Subjects who are estimated inappropriate to this study by the principal investigator and the principal researcher.

Design outcomes

Primary

Measure	Time frame
Symptoms caused by cedar pollen	—

Secondary

Measure	Time frame
Nasal cavity findings, Nasal eosinophil score, Serum cytokine etc.	—

Countries

Japan

Contacts

Public ContactTakao Saito

Otsuka Pharmaceutical Co.,Ltd. Otsu Nutraceuticals Research Institute

Saito.Takao@otsuka.jp077-521-8835

Outcome results